8-K: Philip Morris International Reaffirms Strong 2025 EPS Forecast Amidst Smoke-Free Transition

Philip Morris International Inc. (PMI) reaffirmed its 2025 full-year reported diluted EPS forecast of $7.01 to $7.14 and adjusted diluted EPS forecast of $7.36 to $7.49, representing growth of 12% to 14%.

Summary

• Philip Morris International's Chief Financial Officer, Emmanuel Babeau, presented at the 2025 dbAccess Global Consumer Conference in Paris on June 3, 2025.
• PMI reaffirmed its 2025 full-year reported diluted EPS forecast of $7.01 to $7.14, initially announced on April 23, 2025.
• The company's adjusted diluted EPS forecast for 2025 is $7.36 to $7.49.
• This adjusted EPS forecast represents a projected growth of 12% to 14% compared to the 2024 adjusted diluted EPS of $6.57.
• Excluding a favorable currency impact of $0.10 per share, the projected currency-neutral increase in adjusted diluted EPS is 10.5% to 12.5%.
• The forecast includes a total 2025 adjustment of $0.35 per share.
• As of December 31, 2024, PMI's smoke-free products were available in 95 markets and were used by an estimated 38.6 million adults globally.
• The smoke-free business contributed 42% of PMI's total net revenues in the first quarter of 2025.
• Since 2008, PMI has invested over $14 billion in developing, scientifically substantiating, and commercializing innovative smoke-free products.
• The U.S. FDA has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches, as well as versions of PMI's IQOS devices and consumables, with some also receiving Modified Risk Tobacco Product authorizations.

Sentiment

Score: 8

Explanation: The company reaffirmed a strong double-digit adjusted EPS growth forecast for 2025 and highlighted significant progress in its smoke-free product portfolio, indicating positive operational momentum and strategic execution.

Positives

• Reaffirmation of a strong 2025 full-year adjusted diluted EPS growth forecast of 12% to 14% (10.5% to 12.5% excluding currency impact), indicating consistent financial performance.
• Significant progress in the smoke-free product portfolio, which accounted for 42% of PMI's first-quarter 2025 total net revenues.
• Broad global reach of smoke-free products, available in 95 markets and used by an estimated 38.6 million adults as of December 31, 2024.
• Substantial long-term investment of over $14 billion since 2008 in developing and commercializing innovative smoke-free products.
• Successful attainment of U.S. FDA marketing authorizations and Modified Risk Tobacco Product (MRTP) authorizations for key smoke-free products like IQOS, General snus, and ZYN nicotine pouches.

Risks

• Increases in excise taxes and the implementation of discriminatory tax structures.
• Increasing marketing and regulatory restrictions that could reduce competitiveness, eliminate communication with adult consumers, or ban certain products.
• Health concerns related to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke.
• Litigation related to tobacco and/or nicotine use and intellectual property.
• Intense competition within the consumer goods and tobacco sectors.
• Adverse effects of global and individual country economic, regulatory, and political developments, natural disasters, and conflicts, including the impact of Russia's invasion of Ukraine.
• Changes in adult smoker behavior.
• Impact of natural disasters and pandemics on PMI's business operations.
• Lost revenues due to counterfeiting, contraband, and cross-border purchases.
• Governmental investigations.
• Unfavorable currency exchange rates, currency devaluations, and limitations on the ability to repatriate funds.
• Adverse changes in applicable corporate tax laws.
• Recent and potential future tariffs imposed by the U.S. and other countries.
• Adverse changes in the cost, availability, and quality of tobacco and other agricultural products, raw materials, components, and materials for electronic devices.
• Challenges to the integrity of information systems and the effectiveness of data privacy policies.
• Unsuccessful attempts to introduce, commercialize, and grow smoke-free products, or if regulation or taxation does not differentiate between such products and cigarettes.
• Inability to successfully introduce new products, promote brand equity, enter new markets, or improve margins through increased prices and productivity gains.
• Inability to expand the brand portfolio internally or through acquisitions and the development of strategic business relationships.
• Inability to attract and retain the best global talent, including women or diverse candidates.
• Inability to successfully integrate and realize the expected benefits from recent transactions and acquisitions.
• Lower predictability of smoke-free products performance compared to traditional products.

Future Outlook

PMI reaffirms its 2025 full-year reported diluted EPS forecast of $7.01 to $7.14 and adjusted diluted EPS forecast of $7.36 to $7.49, projecting a currency-neutral increase of 10.5% to 12.5% versus 2024 adjusted diluted EPS. The company continues its long-term ambition to expand into wellness and healthcare areas, aiming to enhance life through seamless health experiences, and remains committed to its goal of completely ending the sale of cigarettes by transitioning to smoke-free products.

Management Comments

• PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on April 23, 2025, of $7.01 to $7.14.
• The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 23, 2025.

Industry Context

PMI is a leading international consumer goods company actively transitioning from traditional combustible cigarettes to smoke-free products. This strategic shift aligns with a broader industry trend towards harm reduction and diversification away from conventional tobacco, driven by evolving consumer preferences, public health concerns, and increasing regulatory pressures. PMI's significant investment ($14 billion since 2008) and substantial market penetration (smoke-free products in 95 markets, 42% of Q1 2025 net revenues from smoke-free) position it as a 'Global Smoke-Free Champion,' indicating a proactive and leading stance in adapting to the changing consumer landscape. The U.S. FDA authorizations for its smoke-free products further highlight regulatory acceptance and potential for market growth in key regions, setting a benchmark for scientific substantiation in the industry.

Comparison to Industry Standards

• PMI's stated goal of 'completely ending the sale of cigarettes' and its substantial investment of over $14 billion since 2008 in smoke-free products positions it as a leader in the tobacco industry's transition towards reduced-risk alternatives, notably ahead of some competitors still heavily reliant on combustible products.
• The company's smoke-free business accounting for 42% of Q1 2025 total net revenues demonstrates significant progress in portfolio transformation compared to peers who may have a lower proportion of revenue from next-generation products.
• FDA authorizations for IQOS, General snus, and ZYN nicotine pouches, including Modified Risk Tobacco Product (MRTP) designations, are a significant competitive advantage, as these are among the first and few such authorizations in the U.S. market, setting a high bar for scientific substantiation that other companies may struggle to meet.
• The estimated 38.6 million adult users of PMI's smoke-free products globally as of December 31, 2024, indicates a strong global adoption rate for its alternative products, potentially outperforming competitors in terms of user base for specific smoke-free categories like heat-not-burn.

Stakeholder Impact

• Shareholders/Investors: The reaffirmation of a strong EPS growth forecast provides confidence in future earnings and potentially supports stock price stability. The continued focus on smoke-free products indicates a clear long-term growth strategy.
• Customers (Adult Smokers): Continued development and availability of a diverse range of smoke-free products offer alternatives for adults who would otherwise continue to smoke, aligning with public health goals.
• Employees: Ongoing investment in smoke-free products and the long-term ambition to expand into wellness and healthcare areas may create new opportunities and contribute to the company's long-term viability and stability.
• Regulatory Authorities: Compliance with FDA authorizations and ongoing scientific substantiation efforts demonstrate the company's commitment to meeting and exceeding regulatory standards in the evolving tobacco and nicotine landscape.

Next Steps

• An archived copy of the webcast of the CFO's presentation at the dbAccess Global Consumer Conference will be available for approximately one year at www.pmi.com/2025dbaccess and on the PMI Investor Relations Mobile Application.

Key Dates

Recommendation

Keywords

Philip Morris International, PMI, EPS forecast, smoke-free products, IQOS, ZYN, nicotine pouches, tobacco, consumer goods, financial outlook, investor conference, dbAccess, adjusted diluted EPS, currency-neutral growth, FDA authorization, Modified Risk Tobacco Product